

17 April 2025

**Physiomics plc
("Physiomics" or the "Company")**

Physiomics Awarded New Contract

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.

The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indications. More specifically, Pharmacokinetic modelling approaches will be utilised to predict the human PK of the molecule in order to support the client to progress this new therapy into their first-in-human study. The project is valued at £47,600 and is projected to complete over the next three months.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are delighted to be working with this new client and supporting their team with the development of their exciting new therapy. This new contract also reflects the progress Physiomics is making in expanding its client base and supporting the development of wider array of new oncology therapies through its services".

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575

Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFQLLFEZLFBBF